TBH.F Teleflex Incorporated
- Market cap
- EUR 5.54B
- P/E
- 79.8x
- P/B
- 1.76x
- ROE
- 38.9%
- Dividend yield
- 0.88%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is TBH.F undervalued?
Graham numberTBH.F trades 149.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Teleflex Incorporated fundamental analysis
No fundamental analysis for Teleflex Incorporated yet.
Teleflex Incorporated stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administ…
Full company profileTeleflex Incorporated financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Teleflex Incorporated annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.87B | 2.15B | 2.45B | 2.60B | 2.54B | 2.81B | 2.79B | 1.71B | 1.70B | 1.99B | 2.25B |
| Gross Profit | 996M | 1.17B | 1.38B | 1.49B | 1.32B | 1.55B | 1.53B | 1.04B | 1.04B | 1.12B | 1.34B |
| Operating Income | 374M | 387M | 400M | 443M | 462M | 559M | 514M | 304M | 254M | 256M | 287M |
| EBITDA | - | 523M | 533M | 634M | 651M | 854M | 731M | 419M | 271M | 303M | 473M |
| Net Income | 237M | 153M | 201M | 461M | 335M | 485M | 363M | 356M | 69.7M | -906M | 1.36B |
| EPS | - | 3.38 | 4.36 | 9.96 | 7.18 | 10 | 7.74 | 7.58 | 1.51 | -20 | 32 |
| Balance Sheet | |||||||||||
| Total Assets | 3.89B | 6.18B | 6.28B | 6.31B | 7.15B | 6.87B | 6.93B | 7.53B | 7.10B | 6.95B | 6.35B |
| Total Liabilities | 1.75B | 3.75B | 3.74B | 3.33B | 3.82B | 3.12B | 2.91B | 3.09B | 2.82B | 3.82B | 2.85B |
| Shareholders' Equity | 2.14B | 2.43B | 2.54B | 2.98B | 3.34B | 3.75B | 4.02B | 4.44B | 4.28B | 3.12B | 3.49B |
| Cash & Short-term Investments | 544M | 334M | 357M | 301M | 376M | 445M | 292M | 223M | 290M | 379M | 430M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 408M | 420M | 437M | 440M | 436M | 651M | 344M | 470M | 636M | 341M | 388M |
| Capital Expenditure | 53.1M | 70.9M | 80.8M | 103M | 90.7M | 71.6M | 79.2M | 90.3M | 90.4M | 95.2M | 72.6M |
| Free Cash Flow | - | 349M | 357M | 337M | 346M | 580M | 263M | 380M | 545M | 245M | 316M |
| Ratios | |||||||||||
| ROE | 11.1% | 6.3% | 7.9% | 15.5% | 10.1% | 12.9% | 9.0% | 8.0% | 1.6% | -29.0% | 38.9% |
| ROA | 6.1% | 2.5% | 3.2% | 7.3% | 4.7% | 7.1% | 5.2% | 4.7% | 1.0% | -13.0% | 21.4% |
| Net Profit Margin | 12.7% | 7.1% | 8.2% | 17.8% | 13.2% | 17.3% | 13.0% | 20.8% | 4.1% | -45.4% | 60.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Teleflex Incorporated dividends
- Dividend yield
- 0.88%
- Forward dividend
- 1.22 EUR
- Payout ratio
- -
- Ex-dividend date
- Nov 16, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 60.3M | 1.36 | - |
| 2024 | USD 63.5M | 1.37 | 91.2% |
| 2023 | USD 63.9M | 1.36 | 17.9% |
| 2022 | USD 63.8M | 1.36 | 17.6% |
| 2021 | USD 63.6M | 1.36 | 13.1% |
| 2020 | USD 63.2M | 1.35 | 18.9% |
| 2019 | USD 62.8M | 1.36 | 13.6% |
| 2018 | USD 62.2M | 1.35 | 31.0% |
| 2017 | USD 61.2M | 1.36 | 40.1% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Teleflex Incorporated
- Insiders 0.67%
- Institutions 99.33%
- Public & others 0.00%
- Shares outstanding 39.7M
- Free float 39.5M
Teleflex Incorporated company profile
- Company name
- Teleflex Incorporated
- Ticker
- TBH.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 15,500
- Fiscal year end
- December
- Address
- 550 East Swedesford Road, Wayne, PA, United States, 19087-1603
- Phone
- 610-225-6800
- Website
- teleflex.com
About Teleflex Incorporated
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.
Teleflex Incorporated management
10- Mr. John R. DerenExecutive VP & CFO · born 1968
- Mr. Daniel V. Logue J.D.Corporate VP, General Counsel & Secretary · born 1974
- Mr. Cameron P. HicksCorporate Vice President of Human Resources & Communications · born 1965
- Mr. Jason WeidmanPresident, CEO & Director
- Mr. Timothy F. DuffyVP & Chief Information Officer
- Mr. Lawrence Soren KeuschVice President of Investor Relations & Strategy Development
- Mr. Howard CyrCorporate VP & Chief Compliance Officer
- Mr. Matt TomkinVice President of Corporate Development
- Mr. James FergusonPresident & GM of Surgical
- Mr. Jake NewmanPresident & GM of Vascular and Emergency Medicine